+27 (0)83 440 0793 mark.fyvie@vxpharma.com
Select Page


As a clinical research and site management organisation, VX Pharma is proficient in offering highly responsive, quick-turnaround services through its dedicated trial sites. As a fully-fledged Site Management Organisation (SMO), we are capable of offering end-to-end service delivery of clinical development across all phases of drug development.

Phase I - IV and Bioequivalence trials

VX Pharma offers clinical trial execution of Phase I to IV and bioequivalence studies through two separate business entities.

Phase I and II trials are conducted through VX Pharma (Pty) Ltd utilising the 23-bed inpatient ward, duly set up with state-of-the-art medical and transit laboratory equipment to effectively deliver on the full spectrum of clinical trial management. The ward is fully equipped with a dedicated patient monitoring area and onsite kitchen facilities that provide tailor made patient meals. In addition the site has patient recruitment and processing areas with dedicated consultation areas. These areas are shared with Syzygy Clinical Research Services (Pty) Ltd, a 100% held subsidiary of Vx Pharma, to execute Phase III and IV studies. The shared resources of the two businesses create exceptional operational and cost synergy resulting in unprecedented value for our services.



At VX Pharma we pride ourselves on a thriving patient database, which is a direct outcome of our innovative recruitment solutions, such as:

  • Direct access to treatment na├»ve patients via local primary care clinics
  • Dedicated patient enrolment function through our study coordinators
  • Dedicated recruitment staff in the field


VX Pharma sees to it that patients stay on trials. Our successful patient retention strategy starts with effective screening and selection of suitable candidates who are likely to remain compliant. We follow through with 24/7 support by making sure patients have access to our sites at any given time of every day, enjoy the comfort of pleasant waiting rooms and fine refreshments, and have a trial investigator at their disposal at each visit. In addition, our study coordinators stay closely integrated with their trial participant community through home visits.


VX Pharma (inclusive of Syzygy Clinical Research Services) has conducted over 150 clinical studies across a wide range of major chronic disease areas. Although we have historically embraced a broad disease-area portfolio we are embarking on a strategy to align the business to the current needs of our sponsors which now places more emphasis on specialised clinical capabilities. Our focus areas moving forward are:

VX Pharma endorses the principle of Good Clinical Practice (GCP) with regard to human subject protection (HSP) as regulated by the U.S. Food and Drug Administration (FDA). At all times, our prime consideration is to execute good quality services without compromising the standard of care of patients.
VX Pharma respects the dignity and rights of trial participants and is committed to safeguarding their well-being. Hence, all our clinical trial proposals for new medical entities are reviewed by a central ethics committee for approval by the South African Health Products Regulatory Agency (SAHPR), a statutory body that regulates the safety and efficacy of medicines and medical devices in South Africa.